Lupin informs about press release

05 Jan 2023 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it enclosed a Press Release as regards launch of a novel fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients under the brand name DIFIZMA® in India.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×